ABBV vs KO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and The Coca-Cola Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-16.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
The Coca-Cola Company · Consumer Defensive
$88.71
+15.5% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
KO has more upside to fair value
(+15.5%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
KO |
| Current Price |
$261.70 |
$88.71 |
| Fair Value Estimate |
$259.04 |
$102.44 |
| Upside to Fair Value |
-1.0%
|
+15.5%
|
| Market Cap |
$462.4B |
$381.7B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
20.8x
|
| Price / Sales |
7.2x
|
7.6x
|
| Price / FCF |
23.6x
|
26.7x
|
| Revenue Growth YoY |
+10.2%
|
+6.7%
|
| Gross Margin |
71.5%
|
61.9%
|
| Operating Margin |
29.3%
|
29.6%
|
| Return on Equity |
-136.5%
|
43.0%
|
| Dividend Yield |
2.61% |
2.37% |
| FCF Yield |
4.25%
|
3.75%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
The Coca-Cola Company is a global non-alcoholic beverage concentrate, brand-management and bottling-system business with products sold in more than 200 countries and territories, supported by powerful trademarks, 2.2 billion daily servings and an entrenched distribution network. Business quality is high: TTM gross, operating and net margins are 61.9%, 29.6% and 28.6%, respectively, ROE is 43.0%, …
Accumulation Zones
| Metric |
ABBV |
KO |
| Zone Low |
$194.28 |
$76.83 |
| Zone High |
$220.18 |
$87.07 |
| In Buy Zone? |
No
|
No
|